MRK.N
Latest Trade
76.73USDChange
0.04(+0.05%)Volume
1,419,717Today's Range
-
77.3452 Week Range
-
92.55As of on the New York Stock Exchange ∙ Minimum 15 minute delay
Previous Close | 76.69 |
|---|---|
Open | 76.75 |
Volume | 1,419,717 |
3M AVG Volume | 219.91 |
Today's High | 77.34 |
Today's Low | 76.40 |
52 Week High | 92.55 |
52 Week Low | 65.26 |
Shares Out (MIL) | 2,524.10 |
Market Cap (MIL) | 193,573.30 |
Forward P/E | 14.71 |
Dividend (Yield %) | 3.18 |
Merck Animal Health Receives U.S. FDA Approval Of Bravecto® Monthly Chews
FDA Grants Priority Review To Merck's Supplemental Biologics License Application For Keytruda (Pembrolizumab) For Second-Line Treatment Of Patients With Relapsed Or Refractory Classical Hodgkin
Zymeworks & Merck Sign New License Agreement
Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company's Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed healthcare providers, such as health maintenance organizations, pharmacy benefit managers and other institutions. Vaccine products consist of preventive pediatric, adolescent and adult vaccines, primarily administered at physician offices.
Industry
Biotechnology & Drugs
Contact Info
2000 Galloping Hill Rd
KENILWORTH, NJ
07033-1310
United States
+1.908.7404000
http://www.merck.com/Executive Leadership
Kenneth C. Frazier
Chairman of the Board, President, Chief Executive Officer
Robert M. Davis
Executive Vice President, Global Services, Chief Financial Officer
Steven C. Mizell
Executive Vice President, Chief Human Resources Officer, Human Resources
Michael T. Nally
Executive Vice President, Chief Marketing Officer
Jennifer L. Zachary
Executive Vice President, General Counsel, Corporate Secretary
Price To Earnings (TTM) | 19.29 |
|---|---|
Price To Sales (TTM) | 4.03 |
Price To Book (MRQ) | 7.39 |
Price To Cash Flow (TTM) | 14.07 |
Total Debt To Equity (MRQ) | 106.84 |
LT Debt To Equity (MRQ) | 82.57 |
Return on Investment (TTM) | 16.29 |
Return on Equity (TTM) | 12.18 |
* MERCK ANIMAL HEALTH RECEIVES U.S. FDA APPROVAL OF BRAVECTO® (FLURALANER) MONTHLY CHEWS
* FDA GRANTS PRIORITY REVIEW TO MERCK’S SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION FOR KEYTRUDA® (PEMBROLIZUMAB) FOR SECOND-LINE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA
* MERCK ANNOUNCES APPOINTMENT OF ORGANON & CO. GENERAL COUNSEL
* ZYMEWORKS - AGREEMENT GRANTS MERCK RIGHT TO DEVELOP ADDITIONAL MULTISPECIFIC ANTIBODY THERAPEUTIC CANDIDATES USING CO'S AZYMETRIC & EFECT PLATFORMS
German drugmaker Merck said on Wednesday it had agreed to supply its potential COVID-19 drug Rebif to European Union countries should orders be placed for the treatment.
* FOGHORN THERAPEUTICS ANNOUNCES COLLABORATION WITH MERCK TO DISCOVER AND DEVELOP NOVEL ONCOLOGY THERAPEUTICS AGAINST TRANSCRIPTION FACTOR TARGET
The U.S. drug regulator declined to approve a combination of Merck & Co Inc's blockbuster cancer drug Keytruda and Eisai Co Ltd's Lenvima as the first line of treatment in patients with liver cancer, the companies said on Wednesday.
The U.S. Food and Drug Administration on Wednesday declined to approve a combination of Merck & Co Inc's blockbuster cancer drug Keytruda and Eisai Co Ltd's Lenvima for use in previously untreated patients with liver cancer.
AstraZeneca Plc and Merck & Co Inc said on Wednesday their blockbuster cancer treatment Lynparza won approval in the European Union for treating patients with a form of pancreatic cancer.
AstraZeneca Plc and Merck & Co Inc said on Wednesday their blockbuster cancer treatment Lynparza won approval in the European Union for treating patients with a form of pancreatic cancer.
* MERCK ANNOUNCES NEW ANALYSES SHOWING ADDITIONAL SAFETY AND EFFICACY DATA FOR INVESTIGATIONAL ISLATRAVIR IN COMBINATION WITH DORAVIRINE IN ADULTS WITH HIV-1 INFECTION
* FDA APPROVES MERCK’S KEYTRUDA® (PEMBROLIZUMAB) FOR THE TREATMENT OF PATIENTS WITH RECURRENT OR METASTATIC CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) THAT IS NOT CURABLE BY SURGERY OR RADIATION Source text for Eikon: Further company coverage:
* TARGOVAX ANNOUNCES COLLABORATION TO EVALUATE ONCOS-102 IN COMBINATION WITH KEYTRUDA[®] IN MESOTHELIOMA
* MERCK’S KEYTRUDA (PEMBROLIZUMAB) APPROVED IN CHINA FOR SECOND-LINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC ESOPHAGEAL SQUAMOUS CELL CARCINOMA WHOSE TUMORS EXPRESS PD-L1 (CPS ≥10)
* MERCK ANNOUNCES THAT V114, ITS INVESTIGATIONAL 15-VALENT PNEUMOCOCCAL CONJUGATE VACCINE, MET SAFETY AND IMMUNOGENICITY OBJECTIVES IN INITIAL PHASE 3 STUDIES IN ADULTS
* MERCK - U.S. FTC HAS GRANTED EARLY TERMINATION OF WAITING PERIOD & CO RECEIVED MERGER CONTROL CLEARANCE FROM AUSTRIAN FEDERAL COMPETITION AUTHORITY Source text for Eikon: Further company coverage:
* FDA APPROVES SECOND BIOMARKER-BASED INDICATION FOR MERCK’S KEYTRUDA® (PEMBROLIZUMAB), REGARDLESS OF TUMOR TYPE
* MERCK - NOTES PRICED INCLUDE $1.0 BILLION OF 0.750% NOTES DUE 2026
* MERCK AND PFIZER’S SGLT2 INHIBITOR STEGLATROTM (ERTUGLIFLOZIN) MEETS PRIMARY ENDPOINT IN VERTIS CV TRIAL FOR PATIENTS WITH TYPE 2 DIABETES AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE
* MERCK & CO INC FILES FOR 4-PART, NOTES OFFERING; SIZE NOT DISCLOSED - SEC FILING Source: (https://bit.ly/2Y5zcDD) Further company coverage:
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.